Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.69 AUD | -1.43% | -6.76% | -12.66% |
04-24 | Mach7 Technologies Posts 20% Annual Recurring Revenue Increase to AU$22.3 Million for March Quarter | MT |
04-24 | Transcript : Mach7 Technologies Limited, Q3 2024 Earnings Call, Apr 24, 2024 |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- The company's enterprise value to sales, at 4.73 times its current sales, is high.
- The company appears highly valued given the size of its balance sheet.
- The company is highly valued given the cash flows generated by its activity.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Over the past twelve months, analysts' opinions have been revised negatively.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
Ratings chart - Surperformance
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-12.66% | 110M | - | ||
-3.25% | 15.01B | - | ||
-38.91% | 2.8B | C- | ||
-12.68% | 2.45B | - | ||
-12.18% | 1.46B | - | - | |
-.--% | 1.12B | - | - | |
+45.93% | 534M | - | ||
+14.96% | 245M | C | ||
-13.03% | 203M | - | - | |
+2.59% | 187M | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- M7T Stock
- Ratings Mach7 Technologies Limited